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Abstract
Cyclosporine A (CsA) is a substrate for cytochrome P450 3A and the efflux transporter P-glycoprotein (P-gp; ), bothABCB1 
abundantly expressed in the kidney. We retrospectively investigated the role of polymorphisms in , and CYP3A4 CYP3A5 ABCB1 
kidney graft donors on recipient renal function and subsequent graft loss, in a long-term cohort of recipients transplanted between
1990 and 2005. DNA from 227 donors and clinical data from the respective 259 recipients were analysed. Graft loss was significantly
associated with the donor variant haplotype (1236T/2677T/3435T vs others haplotype: HR 9.346; 95 CI (2.278 38.461); pABCB1 = % – =
0.0019) and with acute rejection episodes (HR 3.077; 95 CI (1.213 7.812); p 0.0178). The variant haplotype was also associated with= % – =
a greater decrease in renal function (homozygotes for TTT 3.047 mL.min /y; heterozygotes for TTT 4.435 mL.min /y; others − 1 − − 1 − −
2.186 mL.min /y; p 0.0240). polymorphisms in donors influence long-term graft outcome, favouring the decrease in renal1 − = ABCB1 
function and graft loss in transplant recipients receiving CsA.
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Studies ; Genotype ; Graft Rejection ; drug therapy ; genetics ; Haplotypes ; Humans ; Immunosuppressive Agents ; therapeutic use ; Kaplan-Meiers Estimate ; Kidney ; 
physiology ; Kidney Function Tests ; Kidney Transplantation ; physiology ; Male ; Middle Aged ; P-Glycoprotein ; genetics ; Polymorphism, Genetic ; genetics ; physiology ; 
Retrospective Studies ; Risk Factors ; Tissue Donors ; statistics & numerical data ; Young Adult
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Introduction
Cyclosporine A (CsA) is a calcineurin inhibitor which has considerably improved graft outcome in solid organ transplantation.
However, its clinical benefits are balanced by its side effects, mainly chronic nephrotoxicity which remains a major problem in all types of
solid organ transplantation ( ). CsA is a substrate of the efflux transporter P-glycoprotein (P-gp; gene) extruding xenobiotics1 ABCB1 
from the cell ( ). The most frequent polymorphisms of are located in exons 12 (1236 C>T), 21 (2677 G>T) and 26 (3435 C>T).2 ABCB1 
There have been few studies investigating the consequences of polymorphisms on the efficacy or toxicity of immunosuppressiveABCB1 
therapy in renal transplantation. Crettol et al. described higher cyclosporine concentrations in the lymphocytes of carriers of the variant 
3435T allele ( ) suggesting that P-gp could influence CsA activity independently of its effect on the drug bioavailability orABCB1 3 
clearance. However, only a weak association was found between the recipient s haplotype gathering the exon 12, 21 and 26 alleles’ ABCB1 
and acute graft rejection, and no association with graft loss ( ). The impact of the silent 3435 C>T SNP on the pharmacokinetics of CsA is4 
controversial ( ). It has been argued that mRNA stability would be lower when the 3435-T allele is present at exon 26 ( ), or that5 ABCB1 6 
P-gp conformation would be altered as a result of this silent mutation, the rarity of the corresponding codon affecting the timing of
cotranslational folding and insertion of P-gp into the membrane ( ). Since P-gp is highly expressed in renal proximal tubule epithelial7 
cells ( ), its activity in the kidney graft, which carries the donor s and not the recipient s genome, may contribute to CsA toxicity. This was8 ’ ’
confirmed by Hauser (n 97), who showed that the donor s but not the recipient s 3435 variant genotype was associated withet al. = ’ ’ ABCB1 
CsA nephrotoxicity (OR, 13.4; 95  CI, 1.2 to 148; p 0.034) ( ). On the other hand, CsA is a substrate for CYP3A enzymes. Among them% = 9 
CYP3A5 is highly polymorphic: the allele results in an alternative splice site in the pre-mRNA leading to a truncated enzymeCYP3A5 *3 
( ); is the wild-type allele, associated with enzyme activity. It was shown that CYP3A4 kidney expression is much lower10 CYP3A5 *1 
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than that of CYP3A5 (when expressed) and that the oxidative metabolism of CsA in human renal microsomes is strongly dependent to
CYP3A5 activity ( ). It is thus possible that the donor s status for CYP3A5 could also have a role in the accumulation, hence11 –13 ’ in situ 
local toxicity, of CsA.
The goal of this study was to investigate the influence of the donor s polymorphisms in and on graft loss in a large’ CYP3A ABCB1 
retrospective cohort with a long-term follow-up of renal transplant recipients given CsA.
Results
Clinical data
Clinical and demographic characteristics of the 259 recipients who fulfilled the inclusion and exclusion criteria are reported in Table 1 
. In particular, we included recipients for whom there was donor DNA available from an original set of 473 renal transplants, performed at
Limoges University Hospital between 1990 and 2006 (inclusive). Patients  follow up was 72 months on average (ranging from 8 to 190’
months). The grafts came from 227 cadaveric donors with age range of 12 73 years (39 14) and sex ratio of 155/72 (M/F). A total of 20– ±
graft losses (7.7  of recipients) were observed in this cohort within the period considered ( ).% Table 1 
Genotype/haplotype distribution and association with graft loss
Genotyping results were in the Hardy-Weinberg equilibrium and similar to those reported in the literature ( ) ( ). As14 Table 2 
previously described, a strong LD was observed between exons 12, 21, 26 SNPs of (D 0.69, r 0.33; D 0.92, rABCB1 ′12 26 – = 2 12 26 – = ′12 21 – = 2 
0.84; D 0.72, r 0.37). The most probable haplotype could not be inferred in 6 patients because the probability of the 212 21 – = ′21 26 – = 2 21 26 – =
haplotypes proposed was close to 50 . Of the 8 haplotypes identified, the 3 most frequent ones were CGC (40.9 ), TTT (36.2 ) and% % %
CGT (14.1 ), the other five representing 8.8  of patients  haplotypes.% % ’
Univariate analysis showed that patients who received their graft from donors carrying the variant 1236 TT, 2677TT andABCB1 
3435TT genotypes had an increased risk of graft loss ( ) compared to patients whose donors were carriers of the wild-typeTable 3 
genotypes (CC1236, GG2677 and CC3435).
Haplotype analysis revealed that patients who received their graft from a donor carrying the TTT haplotype had an increased risk of
graft loss compared to those whose grafts came from a CGC haplotype carrier (HR 2.616; 95 CI (1.373 4.986); p 0.0035) ( ).= % – = Table 3 
Graft loss episodes occurred in 6/33 (18 ) of the recipients from donors homozygous for the TTT haplotype, 11/123 (9 ) of those with% %
donors heterozygous for TTT and 3/97 (3 ) of hosts of another haplotype.%
No significant association was found between the donor s or CYP3A5 genotype and graft loss ( ).’ CYP3A4 *1B Table 3 
Association of non genetic factors with graft loss
Univariate analysis of non genetic variables revealed a strong association between occurrence of acute rejection (AR  1 episode) and≥
graft loss (HR 2.756; 95 CI (1.095 6.933); p 0.0321) ( ). On the other hand, no significant association between graft loss and= % – = Table 3 
recipients  sex or age, donor s sex or age, cold ischemia time or number of HLA mismatches was found ( ).’ ’ Table 3 
Independent risk factors for graft loss: multivariate analysis
Only the donor s G2677T SNP and acute rejection remained significant in the final multivariate Cox model ( ).’ ABCB1 Table 4 
Patients who received their graft from a donor carrying the 2677TT or the G2677T genotype had a graft loss hazard ratio of 12.0 and 4.7,
respectively as compared to those transplanted from carriers of the GG2677 genotype. Simultaneously, patients who had at least one
episode of acute rejection had a graft loss hazard ratio of 3.1 as compared to those who did not experience acute rejection.
In the final Cox model including the donor s haplotype instead of the SNPs, again only the haplotype and’ ABCB1 ABCB1 ABCB1 
acute rejection remained significant. Patients who received their graft from a donor homozygous or heterozygous for the variantABCB1 
(TTT) haplotype had a graft loss hazard ratio of 9.3 and 3.3, respectively, as compared to those transplanted from carriers of other
haplotype combinations ( ). Simultaneously, patients who had had at least one acute rejection episode had a graft loss hazard ratioTable 4 
of 2.8 as compared to those with no acute rejection episode.
Survival analysis further confirmed that the cumulative incidence of graft loss was significantly higher when donors carried the 
TTT haplotype (p 0.0028) ( ).ABCB1 = Figure 1 
Association of ABCB1 haplotype with renal function
A significantly more important decrease of creatinine clearance over the follow-up period ( CrCl/y) was observed when donors wereΔ
carriers of the variant TTT haplotype (homozygotes for TTT: 3.047  4.008 mL.min per year, heterozygotes for TTT: μ CrCl/y Δ =− ± 1 − μ CrCl/y Δ
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4.435  6.803 mL.min per year and others: 2.186  5.583 mL.min per year; p 0.0240). Similar results were obtained=− ± 1 − μ CrCl/y Δ =− ± 1 − =
when regression analysis of creatinine clearance measured annually was performed and the average slope was compared between the
different haplotype groups (data not shown).
Discussion
Based on the data collected retrospectively in 259 renal transplant patients receiving CsA with a mean follow-up of 72 months (range:
8 to 190 months), we found that the 1236T, 2677T and 3435T variant alleles and the corresponding (1236T-2677T-3435T) variantABCB1 
haplotype in graft donors were associated with a higher risk of graft loss. Multivariate analysis considering this haplotype, the CYP3A5 *3 
and polymorphisms recipients  demographic characteristics, donors  age and sex, graft cold ischemia time, number of HLACYP3A4 *1B ’ ’
mismatches, and occurrence of acute rejection identified the variant haplotype and acute rejection as the only significantABCB1 
predictors of long-term graft survival. Moreover, the decrease in renal function over the follow-up period (estimated as delta creatinine
clearance per year) was more pronounced when the donor was carrier of the TTT haplotype.ABCB1 
This study was based on a long-term collection of donors  DNA samples by the Immunology laboratory of Limoges University’
Hospital and was based on the hypothesis that polymorphisms of the donor s P-gp or CYP3A proteins (reflecting their local activity in the’
kidney graft) could influence CsA long-term nephrotoxicity and finally graft loss. P-gp acts as a transport pump actively excreting CsA
from the epithelial tubular cells into urine. As it is abundantly expressed in these cells, normal P-gp activity in the graft may protect them
from CsA toxicity.
Consistently, Hauser 2004 showed in 97 kidney transplant patients that approximately 40  of kidney recipients transplantedet al., %
from donors homozygous for the 3435T variant allele developed CsA nephrotoxicity within 2.5 years post-transplantation,ABCB1 
compared to only 10  of patients transplanted from donors carrying the heterozygous (C3435T) or the reference (CC3435) genotype ( ).% 9 
In addition, Joy showed using immunohistochemistry that kidney P-gp expression was lower in 39 renal transplant patients exhibitinget al. 
structural signs of nephrotoxicity to calcineurin inhibitors (CNI) than in 32 controls ( ). Finally, a recent study by Naesens showed15 et al. 
in patients on tacrolimus that the donor s and recipient s TT 3435 C>T variant alleles were associated with an increased risk of’ ’ ABCB1 
chronic allograft damage ( ). This group further showed there was no association with tacrolimus exposure suggesting that this outcome16 
is likely to be related to accumulation of tacrolimus in epithelial cells. The authors hypothesized that the recipient s polymorphism is’
significantly linked to the outcome due to important epithelial chimerism after renal transplantation. Although no association between 
polymorphism and graft survival was found at 3 years, they suggested that a longer follow-up would be necessary to observe theABCB1 
progression from chronic histological damage to renal graft loss. Our retrospective study provides convincing evidence of the importance
of the donor s genotype on graft loss in renal transplant patients on CsA with long-term follow-up. Moreover, the analysis of the’ ABCB1 
evolution of renal function showed that when the donor carried the TTT haplotype creatinine clearance declined more rapidly,ABCB1 
leading to a shorter time to graft loss. It is noteworthy that we did not observe a gradual change of renal function with haplotype copy
number. A possible explanation is that creatinine clearance is a continuous variable subject to high variability, and that the number of TTT
homozygotes was too low as compared to heterozygotes to observe a potential additive effect.
Cattaneo recently found that recipients carriers of the T allelic variants of exons 21 and 26 had an increased risk for CsA-relatedet al. 
adverse events, including delayed graft function and lower GFR ( ). In the present study, the analysis of recipient DNA polymorphisms17 
was performed on 9 graft loss episodes only, because 11 recipients with graft loss died before the beginning of this retrospective study, i.e.
before we could collect their DNA (these patients were amongst those transplanted farthest back in time and graft loss may have shortened
their survival). We found no association between recipient haplotype and graft loss (data not shown) but the low number of eventsABCB1 
makes any conclusion difficult to drawn.
In addition to polymorphism, multivariate analysis identified acute rejection as another, already well-known ( ),ABCB1 18 –20 
independent factor of graft loss, however with lower hazard ratio values than the polymorphisms or haplotype.ABCB1 
There are some limitations to this study. First, there is a lack of an independent validation group. It is rare to find recipients with
long-term follow-up data for whom donor DNA is available as can be seen by the paucity of studies in this domain ( , ). When such21 22 
data exist, there is a short retrospective follow-up of recipients ( , ). Despite our efforts and contacts with colleagues, we have been9 16 
unable to find an independent database with a follow-up period as long as for our recipients.
Secondly, we missed data on immunosuppressant blood concentrations, in particular CsA, due to the impossibility to reliably retrieve
these data retrospectively over such a long period of time. Third, precise histological analysis of explanted grafts is missing. Out of the 28
patients who lost their graft, 8 were excluded from the analysis owing to graft loss attributable to clear external causes. The 20 patients
remaining had a graft biopsy at one point in time during the follow-up period. Seventeen of these biopsies allowed histological analysis of
the graft and most (12/17) showed histological damages compatible with CsA toxicity. Unfortunately, case-control comparisons on
histological findings in the whole cohort could not be undertaken because biopsies were not performed in a majority of patients. Finally, it
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is evident that graft loss is the result of multiple other factors, the study of which was beyond the goal of the present work that specifically
aimed to investigate the role of genetic factors from the donor in the occurrence of graft loss, owing to its retrospective design that made it
possible to study this rare and late occurring event.
In conclusion, we found that the variant haplotype of graft donors is associated with a significantly higher risk of graft loss inABCB1 
kidney transplant recipients. It suggests that genetic variations in are predictive of graft outcomes through P-gp influence on localABCB1 
CsA concentration. Our study provides additional and complementary evidence to the results of Naesens who showed that in patientset al. 
receiving calcineurin inhibitors polymorphisms are predictive of the renal graft deterioration independently of graft quality atABCB1 
transplantation ( ). Owing to developments in genetic technology for clinical use, it can be proposed that genotyping for be16 ABCB1 
included as part of systematic genotyping of the donor in routine practice and that the donor haplotype be taken in account in theABCB1 
choice or the doses of the immunosuppressants.
Methods
Patient population
The clinical data-on-file from renal graft recipients between 1990 and 2005, routinely followed as outpatients at Limoges University
hospital were retrospectively studied. The ethics committee of Limoges hospital approved the protocol. Informed consent was obtained
from each living patient, while French Health Authorities have waived the requirement for consent for deceased patients and donors. The
following inclusion criteria were used: recipient age > 18 years; kidney graft from a cadaveric donor (following brain death); patients
treated with CsA (SANDIMMUN  or NEORAL ); functional graft after more than one year posttransplantation; donor s DNA available.® ® ’
The exclusion criteria were: patient age < 18 years; pregnancy; combined kidney and pancreas, heart or liver transplantation; patient
treated with tacrolimus or an mTOR inhibitor; graft survival < 1 year so as to exclude precocious graft loss, which is not due to
nephrotoxicity. Eight patients were excluded from the analysis because they lost their graft as a consequence of a clearly identified cause:
recurrence of the primary kidney disease or glomerulopathy ( ), myeloma ( ), lymphoma ( ), uterus cancer ( ), andde novo 4 1 1 1 
septicaemia ( ). Patients who died with a functional graft were excluded at the time of death (death-censored graft survival). For each1 
patient, the following clinical data were recorded from the medical file by the same nephrologist (JPR) before the genetic study was
carried out: date of birth, sex, HLA mismatches between donor and recipient, duration of cold ischemia, induction therapy,
immunosuppressive drug regimens, treated acute rejection episodes within the period of follow-up (acute rejection proven by histological
examination of a biopsy or treated as acute rejection without biopsy confirmation), creatinine clearance each year and graft survival. The
creatinine clearance was estimated for each patient using the Cockcroft and Gault formula. Patients  decrease in renal function over time’
was estimated by subtracting the last creatinine clearance value available to the value at one year posttransplantation divided by follow-up
duration (delta creatinine clearance per year). The only data available for donors was age and sex.
Donors  DNA bank’
Each donor s genomic DNA was extracted from lymph nodes or spleen lymphocytes by salting out extraction as previously described (’
) and banked by the Immunology laboratory of Limoges University Hospital as part of routine practice.23 
Identification of genotypes
Donor s genotypes for 392 A>G ( allele, rs2740574), 6986 A>G ( allele, rs776746)’ CYP3A4 − CYP3A4 *1B CYP3A5 CYP3A5 *3 
SNPs, and 1236 C>T (exon 12, rs1128503), 2677 G>T (exon 21, rs2032582) and 3435 C>T (exon 26, rs1045642) SNPs wereABCB1 
determined using TaqMan allelic discrimination assays on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems,
Courtaboeuf, France). Primers and probes were purchased from Applied-Biosystems as validated custom or DME assays.
Statistical analyses
Deviations from the Hardy-Weinberg equilibrium were studied using the Fisher s exact test. The effect of gene polymorphisms (SNPs’
or haplotypes) on graft loss was investigated using the Cox proportional hazard model. P values less than 0.05 were considered significant
and 95  confidence intervals were calculated when relevant. For SNPs and haplotypes association analyses, the most frequent allele was%
considered as the reference. For multivariate analysis, the significance of variables in the final model was tested by a backward stepwise
process using the likelihood ratio to evaluate the effect of omitting variables.
After studying the effect of each polymorphism independently, the association of haplotypes with graft loss was analyzed using the
THESIAS program ( ) ( ), based on the maximum likelihood model described by Tregou t and linkedhttp://genecanvas.ecgene.net 24 ë et al. 
to the s.e.m. algorithm. This software was used to estimate pairwise linkage disequilibrium (LD) between polymorphisms. TheABCB1 
extent of disequilibrium was expressed in terms of D  and r .′ 2 
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The most probable haplotypes were inferred for each patient using the PHASE V2.0 program ( ) and for the significant25 
polymorphisms, time-to-event data were estimated using Kaplan-Meier analysis for patient with or without the polymorphism of interest,
and groups were compared using the log-rank test.
One way analysis of variance (ANOVA) was performed to test the influence of significant polymorphisms on delta creatinine
clearance per year.
All statistical analyses were performed using Statview 5.0 (SAS Institute Inc, Cary, NC, USA), except when stated otherwise.
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Figure 1
Kaplan-Meier curves of cumulative survival without graft loss for patients transplanted from donor homozygous carriers, heterozygous or
non-carriers of the TTT haplotype.ABCB1 
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Table 1
Patients  characteristics’
Recipients
n 259
Age (min-max) 54 14 years (19 78)± –
Sex ratio M/F 162/97
Cold ischemia time (min-max) 1195 347 min (303 2580)± –
Number of HLA mismatches (min-max) 3.6 1.2 (0 6)± –
Follow-up period (min-max) 72.0 46.2 months (8.1 190.0)± –
Acute rejection: n ( ) with  1 episode% ≥ 80 (30.9 )%
Graft loss: n ( )% 20 (7.7 )%
Time between transplantation and graft loss (min-max) 78.1 41.1 months (13.8 161.6)± –
Delta creatinine clearance per year (ml.min /year)1 − −3.39 6.07±
Parameters are expressed as mean SD±
Table 2
Frequency and distribution of the studied polymorphisms in donors (n 227)=
Gene Polymorphisms Allelic frequencies (variant allele) Genotype distributions
wt/wt wt/m m/m
ABCB1
1236 C>T 0.427 75/227 110/227 42/227
2677 G>T 0.427 75/227 110/227 42/227
3435 C>T 0.509 59/227 105/227 63/227
CYP3A4 −392 A>G ( )CYP3A4 *1B 0.037 210/227 17/227 0/227
CYP3A5 6986 A>G ( )CYP3A5 *3 0.923 0/227 35/227 192/227
wt: wild type, m: mutated
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Table 3
Univariate analysis (Cox Model) of the influence of the different variables studied on graft loss.
Variable Category2 Hazard ratio CI 95% p
6986 A>G (CYP3A5 * 3) AG vs GG 2.437 0.867 6.850– 0.0910
392 A>G (CYP3A4 − * 1B) AG vs AA 0.913 0.121 6.896– 0.9299
ABCB1 1236 C>T
TT vs CC 8.403 1.733 41.667– 0.0083
CT vs CC 1.825 0.705 4.717– 0.2149
ABCB1 2677 G>T
TT vs GG 10.417 2.105 52.631– 0.0041
GT vs GG 2.174 0.829 5.682– 0.1143
ABCB1 3435 C>T
TT vs CC 3.921 1.059 14.493– 0.0407
CT vs CC 1.211 0.313 4.695– 0.7820
ABCB1 haplotype 1236 C>T/2677 G>T/3435 C>T TTT vs CGC1 2.616 1.373 4.986– 0.0035
Age recipient per year increase 0.995 0.965 1.026– 0.7496
Age donor per year increase 1.030 0.995 1.067– 0.1254
Sex recipient Female vs Male 0.806 0.329 1.977– 0.6398
Sex donor Female vs Male 0.885 0.360 2.178– 0.7906
Acute rejection ≥1 vs 0 2.756 1.095 6.933– 0.0321
Cold ischemia time per min. increase 0.999 0.998 1.001– 0.3218
Total HLA mismatch per mismatch increase 0.885 0.629 1.245– 0.4851
1 Estimation of the risk when carrying the mutated allele the wild type allele calculated with THESIASvs. 
2 For the most frequent category of the variable, taken as reference, HR 1.=
Table 4
Multivariate analysis (Cox Model) for risk of graft loss (taking in account either the three genotypes separately or the corresponding haplotype).ABCB1 
Variable Category Adjusted Hazard ratio Adjusted CI 95% p
ABCB1 2677 G>T
TT vs GG 12.048 2.392 58.823– 0.0025
GT vs GG 4.673 1.020 21.276– 0.0471
Acute rejection ≥1 vs 0 3.077 1.213 7.812– 0.0178
ABCB1 haplotype
TTT/TTT vs other/other 9.346 2.278 38.461– 0.0019
TTT/other vs other/other 3.322 0.918 12.048– 0.0671
Acute rejection ≥1 vs 0 2.849 1.129 7.194– 0.0266
